-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
-
Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune Checkpoint Inhibitor Therapy
By Kara Nyberg, PhD Posted: June 24, 2020 Pneumonitis is a well-known complication associated with immune checkpoint inhibitors (ICI). A collaborative effort between the U.S. Food and Drug Administration (FDA) and Synapse, a consultancy firm, retrospectively analyzed both clinical trial data and real-world data (RWD) taken from the Advocate Aurora Health System to elucidate risk…
-
Karen L. Reckamp, MD, MS
Posted: June 24, 2020 In addition to her roles of Associate Director for Clinical Research at Cedars-Sinai Cancer and Medical Oncology Director of Women’s Guild Lung Institute in the Department of Medicine at Cedars-Sinai Cancer, Karen L. Reckamp, MD, MS, has been named the Director of the Division of Medical Oncology there. Most recently, Dr.…
-
Gideon Blumenthal, MD
Posted: June 24, 2020 Gideon Blumenthal, MD, has transitioned from Deputy Director of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA) to Vice President of Global Regulatory Affairs for Oncology at Merck. Dr. Blumenthal was with the FDA for more than a decade, after more than 12 years of…
-
David LeDuc
Posted: June 24, 2020 David LeDuc has been named Associate Director, Oncology Patient Affairs at Astra-Zeneca. In this role, Mr. LeDuc will be responsible for building and strengthening relationships with key stakeholders and advocates and incorporating the patient voice in all aspects of the company’s work. Mr. LeDuc came to AstraZeneca from the Go2 Foundation…
-
Multidisciplinary Tumor Board: A Single Institution’s Perspective
By Ari Rosenberg, MD Posted: June 24, 2020 As 7:00 AM approaches, the ninth-floor conference room slowly fills as team members file in and find their seats. The senior radiation oncologist identifies his seat in the front row, carefully placing his stack of index cards on the table before him, each identifying a patient’s…
-
Tobacco Use Assessment and Cessation Support: More Important Now Than Ever
It is well known that ongoing tobacco use is associated with poorer survival in patients with cancer, and the IASLC has emphasized this message.1 The Declaration from IASLC: Tobacco Cessation After Cancer Diagnosis reminds us that tobacco assessment and cessation support are key components of cancer care. Over the past months, COVID-19 has swept the…
-
Single-Agent Pembrolizumab Active Against STK11- and KEAP1- Mutated NSCLC According to KEYNOTE-042 Analysis
By Kara Nyberg, PhD Posted: June 24, 2020 Genomic alterations in STK11 and KEAP1 represent two of the most common and potent contributors to a cold tumor immune microenvironment in nonsquamous NSCLC. Although prior research has shown that these mutations are tied to poor outcomes in patients treated with immune checkpoint blockade, particularly in the…
-
Losing the Personal Touch in the Digital World
By Rebecca Matthias, MD Posted: June 10, 2020 Ms. Matthias is a patient with lung cancer who, along with so many, has transitioned to telehealth. Ms. Matthias lives in Oshkosh, Wisconsin, but she typically travels to Michigan for her preferred provider. Below are her thoughts on the success of patient–physician communication during the COVID-19…
-
Adapting to the New Virtual Environment: Telehealth Can Be a Patient-First Approach
By Brendon Stiles, MD Posted: June 10, 2020 Imagine living in a city with more than 180,000 reported cases of COVID-19 and more than 24,000 deaths. Next imagine asking your patients with lung cancer to come into the heart of that city, to a hospital that has cared for hundreds of those patients infected…
-
Telehealth Is Not a One-Size-Fits-All Approach
By Narjust Duma, MD Posted: June 10, 2020 During the past 8 weeks, we have heard how many of our colleagues and cancer centers are switching to telehealth. Two things are clear during this pandemic. The first is that cancer centers cannot wait—most cancer procedures and treatments are not elective, and our patients need their…
View ILCN Archives
Provider Resources
Popular Articles